Skip to main content

Management

 

Peter Wolpert, CEO and founder, M.Sc. Eng., M.Sc. Econ.
Born 1969. Has worked for the company since 2006. Peter Wolpert has more than 15 years' experience as a CEO, strategy consultant and entrepreneur, and is chairman of the board of Viscogel AB. He was a co-founder of Accuro Immunology, Ibility and Viscogel, CEO of Athera Biotechnologies and a strategy consultant at McKinsey & Co.

Shareholding: 435 399 shares through Wolco Invest AB and 125 000 employee stock options (125 000 shares may be subscribed to, based on the employee stock options).
 

 

Martin Ingman, VP Sales & Marketing, M.Sc. Econ.
Born 1962. Has worked for the company since 2008. Martin Ingman has more than 20 years' experience of leading positions in Life Science at Astra AB (publ) (now AstraZeneca), Q-Med AB and Carema Care.
Shareholding: 1 100 shares and 60 000 employee stock options (60 000 shares may be subscribed to, based on the stock options).

 

Kjell Rensfeldt, VP Research and Development, Chief Medical Officer, MD, M.Sc. Econ.
Born 1957. Has worked for the company since 2007. Kjell Rensfeldt has ten years' industrial experience of leading positions within Biogen Idec and Q-Med. Dr Rensfeldt also has ten years' clinical experience and has undergone specialist training in urology.
 
Shareholding: 10 000 shares and 100 000 employee stock options (100 000 shares may be subscribed to, based on the stock options).

 

Anna Ljung, CFO , M.Sc. Econ.
Born 1980. Has worked for the company since 2006. Anna Ljung has served as the CFO of Athera Biotechnologies AB and Lipopetide AB, and worked as an independent consultant in the field of technology licensing.
 
Shareholding: 12 000 shares and 80 000 employee stock options (80 000 shares may be subscribed to, based on the employee stock options).

 

Jeff Vernimb, General Manager Moberg Pharma North America,  B. Sc.
Born in 1963, head of Moberg Pharma’s North American operations. Jeff Vernimb recently joined Moberg Pharma (December, 2014). Previous experience includes senior level sales, marketing and Rx-to-OTC switch roles in both large and smaller entrepreneurial consumer healthcare companies including Pfizer, Novartis, Dynova Labs and Insight Pharmaceuticals.

Shareholding: 5 500 shares and 150 000 employee stock options (150 000 shares may be subscribed to, based on the employee stock options).

Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development.
Born 1958. Has worked for the company since 2013. Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD and Pharmacia & Upjohn among others. Torbjörn Wärnheim has a broad experience of pharmaceutical development of Rx- and OTC-products, and is associate professor at Royal Institute of Technology (KTH), Stockholm, with a research background within surface chemistry and physical chemistry of lipids.

Shareholding: 10 000 employee stock options (10 000 shares may be subscribed to, based on the employee stock options).

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.